Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232015 | 0.85 | — | — | |
| Bromide SCHEMBL1271251 | 0.83 | ACHE (0.47) | TSHRACHETDP1ALDH1A1 | |
| SCHEMBL11830057 | 0.78 | ACHE (0.42) | ACHETDP1ALDH1A1 | |
| Formic Acid SCHEMBL23467134 | 0.73 | CYP2A6 (0.41) | TSHRACHETDP1ALDH1A1GAA | |
| SCHEMBL9196417 | 0.71 | ACHE (0.35) | ACHETDP1ALDH1A1 | |
| SCHEMBL5487650 | 0.71 | — | — | |
| SCHEMBL663624 | 0.69 | TSHR (0.48) | TSHRACHETDP1ALDH1A1 | |
| P-Xylene SCHEMBL27971620 | 0.68 | ACHE (0.67) | TSHRACHETDP1ALDH1A1GAA | |
| Bromide SCHEMBL2959626 | 0.67 | TSHR (0.46) | TSHRACHETDP1ALDH1A1 | |
| SCHEMBL464793 | 0.63 | ACHE (0.57) | TSHRACHETDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507830-B2 | Process for preparing unsymmetrical biaryls and alkylated aromatic compounds from arylnitriles | PHARMACORE, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-6962999-B2 | Process for preparing unsymmetrical biaryls and alkylated aromatic compounds from arylnitriles | PHARMACORE, INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050124808-A1 | Process for preparing unsymmetrical biaryls and alkylated aromatic compounds from arylnitriles | DSM I.P. ASSETS B.V. (NL) | 2005-06-09 | — | — | US | disclosed |
| US-20030100760-A1 | Process for preparing unsymmetrical biaryls and alkylated aromatic compounds from arylnitriles | DSM N.V. (NL) | 2003-05-29 | — | — | US | disclosed |
| EP-1279656-A2 | Process for preparing unsymmetrical biaryls and alkylated aromatic compounds from arylnitriles | DSM N.V. (NL) | 2003-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100760-A1 | Process for preparing unsymmetrical biaryls and alkylated aromatic compounds from arylnitriles | AHR, PAH, DDT | TSHR 2211/4885ACHE 1403/4885TDP1 3354/4885 |
| US-20050124808-A1 | Process for preparing unsymmetrical biaryls and alkylated aromatic compounds from arylnitriles | AHR, PAH, DDT | TSHR 2211/4885ACHE 1403/4885TDP1 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.